Navigation Links
Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients
Date:8/21/2014

eated hemophilia A. Patients received treatment twice weekly (45 IU/kg) or on-demand, and were followed for six months. The primary objective of the study was the reduction in ABR during the treatment period compared to on-demand treatment. The study also evaluated the safety and immunogenicity of the compound when administered on either prophylaxis or on-demand treatment regimens.

Baxter expects to submit a Biologics License Application (BLA) for BAX 855 to the U.S. Food and Drug Administration (FDA) before the end of 2014 and will present additional data in the coming months. In addition to an ongoing continuation study for patients who have completed the pivotal trial, the company is initiating a Phase 3, prospective, open-label, multi-center study to evaluate the safety and efficacy of BAX 855 among 60 previously treated patients under the age of 12 with severe hemophilia A. Consistent with guidelines published by the European Medicines Agency (EMA) that require a study in children less than 12 years of age prior to filing, Baxter expects to file a Marketing Authorization Application with the EMA upon the completion of the pediatric study.

BAX 855 is based on ADVATE, a full-length FVIII molecule with more than 10 years of real-world experience. Through a collaboration with Nektar Therapeutics (NASDAQ: NKTR), BAX 855 leverages proprietary PEGylation technology designed to extend the duration of activity of proteins in the body. This proprietary technology has been used for over 10 years in a number of approved medicines that treat chronic or serious conditions.

About ADVATE
ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency or classic hemophilia) for:

  • Control and prevention of bleeding episodes.
  • Perioperativ
    '/>"/>

SOURCE Nektar Therapeutics; Baxter International Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
2. Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
3. FDA Approvals, Dividends, New Technologies, and Solid Margins Increase Shareholder Value - Research Report on Abbott, Baxter, CareFusion, Haemonetics, and CR Bard
4. Early Morning Insight: Baxter, CareFusion, Unilife, and Mindray Medical
5. Israeli Medical Device Company FlowSense Acquired by Baxter
6. Legal Actions, Quarterly Dividends, Collaborations, and New Appointments - Research Report on Johnson & Johnson, Zoetis, Abbott, Teva Pharmaceuticals, and Baxter
7. United States Regenerative Medicine Market Analysis to 2016 Featuring Baxter, Medtronic, Stryker & Zimmer
8. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
9. Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific
10. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
11. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Omnicell, Inc. (Nasdaq: OMCL ) a leading ... they will present at the UBS 21st Annual Global Healthcare ... Omnicell Speakers: Rob Seim, vice president ... DevelopmentDate: Tuesday, February 8, 2011Time: 11:00 a.m. ESTLocation: ...
... LLC , ( www.curemark.com ), a drug research and ... recently hosted New York Senator Kirsten Gillibrand as she ... creation, locally and nationally.  Speaking at Curemark, which is ... proposal to expand, simplify and make permanent the Research ...
Cached Medicine Technology:Omnicell to Present at the UBS 21st Annual Global Healthcare Services Conference 2Curemark Hosts New York Senator Kirsten Gillibrand 2Curemark Hosts New York Senator Kirsten Gillibrand 3
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... receive effective, less expensive care from a clinic that functions ... of dedicated health care professionals, a new study shows. ... either hospitalization or a trip to the emergency room when ... the University of Texas in Houston versus usual care, according ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- Overeating is common during the ... in moderation, an expert says. "Don,t arrive at a ... if you know you,ll be attending a party, but deprivation ... lead dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., ... eat healthy during the day and even to have a ...
(Date:12/25/2014)... By Dennis Thompson ... -- Researchers could be closing in on a "fountain of ... improve the health of older adults, a new study suggests. ... when given a drug that targets a genetic signaling pathway ... maker Novartis report. The experimental medication, a ...
(Date:12/25/2014)... December 25, 2014 Thousands of transvaginal ... forward in a number of multidistrict litigations currently underway ... Bernstein Liebhard LLP reports. According to an Order issued ... convene a Joint Status Conference in all of the ... have been directed to submit a proposed agenda to ...
(Date:12/25/2014)... 2014 Plugin creators from Pixel Film ... fully customizable business presentation tool made specifically for ... 5k business tool, users can now display their stats ... Pixel Film Studios. “ProFire 5k gives users a multiple ... professionalism to a presentation” , Pixel Film Studios takes ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... 19 The National Retail,Federation welcomed last night,s ... a House subcommittee to adopt the Senate,s version,when ... today. "The Senate bill is a strong ... while balancing the interests of employers," said NRF ...
... to treatments for diseases such as diabetes and Alzheimer,s , ... successfully reprogrammed adult stem cells from the testes of male ... blood vessels, contractile cardiac tissue, and brain cells. , If ... from humans, they may offer a source of new therapies ...
... plentiful this year, but inoculation rates are low, officials ... many Americans aren,t getting vaccinated for the flu, including ... workers -- U.S. health officials warned Wednesday. , "Despite ... still failing to protect a large proportion of people," ...
... accessed and plentiful, adult stem cells found in a male ... range of tissue types to help him fight disease -- ... , That,s the promise of a breakthrough study in mice ... New York City, who report their findings in the September ...
... International,( http://www.activator.com ), pioneer in chiropractic instrument,manufacturing and ... alliance,with three leading chiropractic companies to create the ... doctors improve the level of,care they provide patients, ... "What,s new about the Activator Advantage seminars is ...
... WASHINGTON, Sept. 19 More Americans will,have access ... bipartisan legislation passed by the U.S. Senate. The,"Mental ... plans that offer,mental health benefits to provide parity ... limitations. (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ) ...
Cached Medicine News:Health News:Retailers Welcome Senate Passage of Mental Health Parity Bill, Urge House to Adopt Senate Version at Subcommittee Markup 2Health News:Stem Cells From Testes Produce Wide Range of Tissue Types 2Health News:More Americans Urged to Get Flu Shots 2Health News:More Americans Urged to Get Flu Shots 3Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 2Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 3Health News:Stem cells in adult testes provide alternative to embryonic stem cells for organ regeneration 4Health News:New Seminar Series from Activator Methods Teaches Doctors a Unique Approach to Improving Nation's Chiropractic Care: Focus on the Patients 2
... The Burdick EK-10 single-channel,electrocardiograph ... touch membrane keypad. It ... make a quick and,accurate ... ergonomically,designed with a built ...
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... CSV-1000LanC 10% test face is ... uses the Landolt C in ... targets. The targets are presented ... is very useful for evaluating ...
... is used to evaluate both low contrast acuity ... and 12.5%) of LogMAR acuity (20/16 to 20/100) ... as the two spatial frequencies of 6 and ... for cataract documentation because eye doctors can document ...
Medicine Products: